UPC judge and Regeneron counsel urge lobbying to improve court's transparency

Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

2 January 2024 District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.

Big Pharma

‘A huge shame’: UPC denies access to pleadings and evidence in Sanofi v Amgen

26 September 2023 An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

Big Pharma

‘A huge shame’: UPC denies access to pleadings and evidence in Sanofi v Amgen

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

Big Pharma

‘A huge shame’: UPC denies access to pleadings and evidence in Sanofi v Amgen